



Olema Oncology to Participate in Upcoming Investor Conferences

February 4, 2026

SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- [Olema Pharmaceuticals, Inc.](#) ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:

Guggenheim Securities Emerging Outlook: Biotech Summit

Date and Time: February 11, 2026 at 10:00 a.m. ET

Format: Fireside Chat

Location: New York, NY

Citi's 2026 Virtual Oncology Leadership Summit

Date and Time: February 19, 2026 at 1:00 p.m. ET

Format: Fireside Chat

Location: Virtual

Oppenheimer 36th Annual Healthcare Life Sciences Conference

Date and Time: February 26, 2026 at 8:00 a.m. ET

Format: Fireside Chat

Location: Virtual

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema's investor relations website at ir.olema.com.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact

Courtney O'Konek

Vice President, Corporate Communications

Olema Oncology

media@olema.com